Archives: Agenda

• The Rise of China’s Biotech Industry: The Chinese government’s “Made in China 2025” strategy and its impact on biotech innovation
• The role of China’s National Medical Products Administration (NMPA) in accelerating drug approvals
• The Role of Venture Capital in China’s Biotech Boom; How Chinese VCs and state-backed funds are fueling biotech startups and the differences between U.S. and Chinese biotech funding models
• Competitive Pressure on U.S. Biotech Firms
• Regulatory & Geopolitical Challenges: The impact of U.S.-China trade tensions and export controls on biotech collaboration

Moderator:

Claire Qin, Chief Strategy Officer, Intelligen AI; BioPharma Investor

中国生物科技产业迅猛发展，在药物研发、临床试验及全球市场拓展方面对美国生物科技企业构成日益激烈的竞争。凭借政府强力支持、资本优势及创新疗法管线的持续扩充，在风险投资（VC）加持下的中国生物科技企业正在重塑行业格局。本环节将深入分析竞争态势、美国企业面临的挑战以及全球生物科技创新的未来走向。

• 中国生物科技产业崛起：”中国制造2025″战略对生物科技创新的推动效应
• 监管加速作用：中国国家药品监督管理局（NMPA）在新药审批中的角色演进
• 资本驱动力量：中美国际资本运作模式差异——中国风险投资与政府基金如何赋能生物科技初创企业
• 美国企业的竞争压力：核心技术与市场份额的双重挑战
• 监管与地缘政治因素：中美贸易摩擦及出口管制对生物科技合作的影响

主持嘉宾:
秦祯，首席战略官，Intelligen AI

• Key trends in the evolving regulatory landscape leading to accelerated approval timelines, elevated quality standards and unlocking new opportunities for drug discovery.
• Key trends driving market momentum leading to an increased market investment, innovation dynamics, and the rapid growth of China’s healthcare sector.
• The future of clinical trials in China: China’s clinical trial landscape is evolving from a solid foundation into a global powerhouse for drug development and innovation.

• 监管环境变革关键趋势：加速审批进程、提升质量标准，为药物研发开启新机遇
• 市场动能核心驱动力：投资规模扩大、创新活力迸发，推动中国医疗健康产业快速增长
• 中国临床试验未来展望：从坚实基础迈向全球药物研 发与创新的领军地位